Cephalon Strategy: Four NDAs In 2005-2006 To Double Firm’s Size
This article was originally published in Pharmaceutical Approvals Monthly
Cephalon goal of four NDA submissions in 14 months is on-track, with approvals forecast to double size of company by 2008. Pediatric sales force of 250 to be hired to detail modafinil for ADHD, with debut slated for early 2006. FDA rejects trade name Attenace. OraVescent breakthrough cancer pain NDA slated for Q3 2005; Gabitril sNDA for generalized anxiety in Q1 2006
You may also be interested in...
Cephalon submits an NDA for its effervescent buccal fentanyl product OraVescent. Announced Sept. 6, the application seeks an indication for management of breakthrough pain in patients with cancer who are already receiving or who are tolerant to opioid therapy for underlying persistent pain. "This NDA, submitted on schedule, is the fourth of five new product opportunities that Cephalon is pursuing over a 15-month period," the firm said. Cephalon previously indicated that its goal of achieving four NDA approvals in 2005-2006 could double the firm's size by 2008 (1Pharmaceutical Approvals Monthly May 2005, p. 13). The OraVescent NDA includes one pivotal trial with statistically significant pain improvements and interim analyses from three ongoing Phase III trials in opioid-tolerant patients...
Johnson & Johnson's McNeil Consumer & Specialty Pharma unit will add Cephalon's attention deficit/hyperactivity disorder treatment modafinil to its pediatric portfolio under a Sept. 1 co-promotion pact
Cephalon on track to file its insomnia agent Nuvigil during the first quarter, firm says